Opposite to our previous finding that PD-1 expression in the tumor tissue does not translate to adverse outcome [15], we observed that pretreatment sPD-1 levels correlated with more aggressive disease and unfavorable outcomes in our selected, clinically high-risk patient population. The gene discussed is PDCD1; the disease is neoplasm.